Comparison of Infliximab and Adalimumab in Biologic-Naive Patients With Ulcerative Colitis: A Nationwide Danish Cohort Study

Keyphrases

• Ulcerative Colitis 100%
• Adalimumab 100%
• Infliximab 100%
• Naïve Patients 100%
• Biologic-naïve 100%
• Hazard Ratio 50%
• Denmark 37%
• High Risk 37%
• Hospitalization 37%
• Serious Infection 37%
• Nave 25%
• Propensity Score Matching 25%
• All-cause Hospitalization 25%
• Clinical Characteristics 12%
• Register-based 12%
• Matched Cohort Study 12%
• Hospitalization Risk 12%
• Abdominal Surgery 12%
• Disease Severity 12%
• Biological Agents 12%
• Major Abdominal Surgery 12%
• Making Decisions 12%
• Health Care Use 12%
• Politicians 12%
• Health Policy 12%
• Surgery Risk 12%
• Modulator Therapy 12%
• Nationwide Registers 12%
• Healthcare Providers 12%
• Patient Healthcare 12%
• Immune Modulation 12%
• Propensity Score Matching Study 12%

Immunology and Microbiology

• Propensity Score Matching 12%